Home

vanagas našlys Praktikavo event free survival vs overall survival Pridėti varzybos Audros

Recurrence-free survival versus overall survival as a primary endpoint for  studies of resected colorectal liver metastasis: a retrospective study and  meta-analysis - The Lancet Oncology
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis - The Lancet Oncology

Cureus | Does Timing of Completion Radical Cholecystectomy Determine the  Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center  Retrospective Analysis | Media
Cureus | Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center Retrospective Analysis | Media

Review Article Clinical endpoints in oncology - a primer
Review Article Clinical endpoints in oncology - a primer

Event-free survival (EFS) and overall survival (OS) according to risk... |  Download Scientific Diagram
Event-free survival (EFS) and overall survival (OS) according to risk... | Download Scientific Diagram

KoreaMed
KoreaMed

Survival (time to event) Outcomes | Health Knowledge
Survival (time to event) Outcomes | Health Knowledge

Clinical Trial Endpoints for Oncology Studies
Clinical Trial Endpoints for Oncology Studies

Wilms tumour event-free and overall survival in Southern and Eastern  Europe: Pooled analyses of clinical data from four childhood cancer  registries (1999–2017) - ScienceDirect
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - ScienceDirect

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS | NEJM  Evidence
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS | NEJM Evidence

Event-free survival at 24 months is a robust surrogate endpoint for  long-term survival in pediatric, adolescent, and adult T cell lymphoblastic  lymphoma | SpringerLink
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink

Progression-free survival (PFS), event-free survival (EFS), and overall...  | Download Scientific Diagram
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram

Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall  Survival after Relapse in Childhood Medulloblastoma
Cancers | Free Full-Text | Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children |  NEJM
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children | NEJM

Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival  as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal  Adenocarcinoma
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

Kaplan-Meier curves for (A) event-free survival and (B) | Open-i
Kaplan-Meier curves for (A) event-free survival and (B) | Open-i

Improved survival and MRD remission with blinatumomab vs. chemotherapy in  children with first high-risk relapse B-ALL | Leukemia
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL | Leukemia

Kaplan-Meier plot of event-free survival (EFS) and overall survival... |  Download Scientific Diagram
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram

Exploring the Effects of Early Censoring and Analysis of Clinical Trial  Survival Data on Effectiveness and Cost-effectiveness Estimation through a  Case Study in Advanced Breast Cancer - Adrian Bagust, Sophie J. Beale,
Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer - Adrian Bagust, Sophie J. Beale,

Event-free survival and overall survival (A) Event-free survival for... |  Download Scientific Diagram
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram

OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND  10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases

Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know

Survival analysis in hematologic malignancies: recommendations for  clinicians | Haematologica
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica

A correlation analysis to assess event-free survival as a trial-level  surrogate for overall survival in early breast cancer - eClinicalMedicine
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine

Rituximab in addition to LMB-based chemotherapy regimen in children and  adolescents with primary mediastinal large B-cell lymphoma: results of the  French LMB2001 prospective study | Haematologica
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study | Haematologica

Blood and tissue biomarker analysis in dogs with osteosarcoma treated with  palliative radiation and intra-tumoral autologous natural killer cell  transfer | PLOS ONE
Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer | PLOS ONE